IRIS
RIZZOLI, Vittorio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.022
AS - Asia 6.617
EU - Europa 4.305
SA - Sud America 784
AF - Africa 306
Continente sconosciuto - Info sul continente non disponibili 113
OC - Oceania 2
Totale 19.149
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.791
SG - Singapore 2.374
CN - Cina 2.018
VN - Vietnam 963
IE - Irlanda 763
FI - Finlandia 741
SE - Svezia 739
BR - Brasile 603
UA - Ucraina 564
DE - Germania 550
HK - Hong Kong 439
TR - Turchia 271
IT - Italia 219
FR - Francia 203
ZA - Sudafrica 200
BD - Bangladesh 183
NL - Olanda 183
CA - Canada 155
GB - Regno Unito 115
IN - India 91
AR - Argentina 70
RU - Federazione Russa 51
CI - Costa d'Avorio 42
MX - Messico 40
EC - Ecuador 39
IQ - Iraq 33
BE - Belgio 32
JP - Giappone 32
RO - Romania 25
PL - Polonia 24
PH - Filippine 23
ID - Indonesia 22
IR - Iran 22
CO - Colombia 21
ES - Italia 21
PK - Pakistan 18
TH - Thailandia 17
TW - Taiwan 17
MA - Marocco 16
CZ - Repubblica Ceca 15
EU - Europa 15
UZ - Uzbekistan 14
LT - Lituania 13
UY - Uruguay 12
SA - Arabia Saudita 10
VE - Venezuela 10
AT - Austria 9
CL - Cile 9
PY - Paraguay 9
AE - Emirati Arabi Uniti 8
JO - Giordania 8
KR - Corea 8
PE - Perù 8
DO - Repubblica Dominicana 7
EG - Egitto 7
JM - Giamaica 7
KE - Kenya 7
LV - Lettonia 7
CR - Costa Rica 6
MY - Malesia 6
TN - Tunisia 6
AL - Albania 5
AZ - Azerbaigian 5
DZ - Algeria 5
ET - Etiopia 5
KZ - Kazakistan 5
NP - Nepal 5
HN - Honduras 4
IL - Israele 4
NG - Nigeria 4
SK - Slovacchia (Repubblica Slovacca) 4
CH - Svizzera 3
HU - Ungheria 3
LK - Sri Lanka 3
NI - Nicaragua 3
OM - Oman 3
SN - Senegal 3
AO - Angola 2
BB - Barbados 2
BG - Bulgaria 2
BO - Bolivia 2
CY - Cipro 2
GE - Georgia 2
GR - Grecia 2
KG - Kirghizistan 2
LB - Libano 2
LU - Lussemburgo 2
MD - Moldavia 2
PS - Palestinian Territory 2
PT - Portogallo 2
RS - Serbia 2
SC - Seychelles 2
XK - ???statistics.table.value.countryCode.XK??? 2
AU - Australia 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CM - Camerun 1
CU - Cuba 1
Totale 19.034
Salva come PNG Salva come JPEG
Città #
Singapore 1.159
Dublin 763
Ashburn 723
Chandler 712
Jacksonville 654
San Jose 597
Beijing 458
Hong Kong 405
Santa Clara 392
Ho Chi Minh City 279
Council Bluffs 278
Dearborn 253
Nanjing 238
Izmir 227
Boardman 226
Dallas 221
Hanoi 211
Johannesburg 191
San Mateo 186
Princeton 160
Los Angeles 156
Ann Arbor 141
Lauterbourg 141
Toronto 108
Shanghai 104
New York 100
Wilmington 98
Shenyang 88
Nanchang 82
Helsinki 76
Kunming 74
Hefei 73
Munich 70
Hebei 65
Düsseldorf 63
Jinan 63
Buffalo 62
São Paulo 56
Parma 50
Des Moines 49
Da Nang 47
Haiphong 45
Abidjan 42
Woodbridge 40
Changsha 39
Marseille 38
Guangzhou 37
Tianjin 37
Jiaxing 35
Bremen 33
Moscow 33
Brussels 32
Columbus 31
Seattle 31
Pune 30
Kocaeli 26
Leawood 25
Stockholm 24
Turku 24
Zhengzhou 24
Tokyo 23
Frankfurt am Main 22
Grafing 22
Warsaw 22
Atlanta 21
Brooklyn 21
Houston 21
Hải Dương 21
Hangzhou 20
Montreal 20
Augusta 19
Norwalk 19
San Francisco 18
London 17
Phoenix 17
Rome 17
Ningbo 16
Orem 16
Amsterdam 15
Focsani 15
Milan 15
Rio de Janeiro 15
Bologna 14
Mestre 14
Boston 13
Guayaquil 13
Lanzhou 13
Monmouth Junction 13
Nuremberg 13
Pittsburgh 13
Tashkent 13
Ardabil 12
Chongqing 12
Denver 12
Fremont 12
Haikou 12
Thái Nguyên 12
Biên Hòa 11
Chicago 11
Quito 11
Totale 11.361
Salva come PNG Salva come JPEG
Nome #
Diabetes impairs hematopoietic stem cell mobilization by altering niche function 257
Angiopoietin-1 and Osteopontin Expression by CD138+ Myeloma Cells Rather Than VEGF and CD45 Correlates with Bone Marrow Angiogenesis in Multiple Myeloma Patients at the Diagnosis 232
Are the Myeloma bone microevironment cells tumoral or not? 228
The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment 209
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 196
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 187
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 186
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 185
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia 181
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 180
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 177
Angiopoietin-1 and osteopontin expression by CD138+myeloma cells rather than VEGF and CD45 correlates with bone marrow angiogenesis in Multiple Myeloma patients at the diagnosis. 177
Amifostine (WR-2721) selective protection against melphalan genotoxicity 175
Chemokine receptors CXCR3 and CXCR4 expression in B cell and plasma cell malignancy 174
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 171
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 169
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation 165
Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. 164
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 163
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 162
Angiopoietins expression by human myeloma cells 161
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. 161
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 161
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 159
A translocation t(4;13)(q21;q14) as single clonal chromosomal abnormality in a parathyroid adenoma 158
Angiogenic switch in multiple myeloma patients 154
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 154
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 154
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 152
Angiogenic properties of human myeloma cells: role of angiopoietin system 151
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis 151
Autologous bone marrow transplantation in acute myeloid leukemia: a single center experience 151
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 150
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 149
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 149
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 148
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 148
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment 147
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 146
Bleomycin Genotoxicity and Amifostine (WR-2721) Cell Protection in Normal Leukocytes versus K562 Tumoral Cells 146
The new tumor suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro-angiogenic molecules by myeloma cells and suppresses hypoxia inducible factor (HIF)-1{alpha} activity being involved in myeloma-induced angiogenesis. 146
Analysis of lineage involvment in Philadelphia chromosome positive acute lymphoblastic leukaemia 144
Ectopic production of osteopontin by human myeloma cells and its involvement in myeloma induced angiogenesis 144
Alterations of microenvironment in multiple myeloma patients: Interactions between myeloma cells and osteoprogenitor cells 143
Do human myeloma cells directly produce basic FGF? 142
Angiopoietin-1 and myeloma-induced angiogenesis 139
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease 138
EPIRUBICIN PLUS G-CSF ELICITED PERIPHERAL BLOOD PROGENITOR CELL MOBILIZATION IS SIGNIFICANTLY ENHANCED BY AMIFOSTINE 137
Macrophage inflammatory protein (MIP)-3 alpha/CCL20 and its receptor CCR6 are overexpressed in the bone microenvironment and involved in osteoclast formation in multiple myeloma patients. 137
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: potential relationship with myeloma-induced angiogenesis 136
A distintive nuclear morfology in three cases of acute myeloid leukaemia associated with loss HLA-DR expression and FTL3 internal tandem duplication 136
Expression and role of chemokine receptor CXCR3 in multiple myeloma 135
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients 135
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 133
Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation. 131
Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation. 130
Assessment of the efficacy of a last-generation polyvalent immunoglobulin in the treatment of idiopathic thrombocytopenic purpura. 129
Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets 128
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent anti-tumor activity in vivo against human multiple myeloma xenograft model. 128
Angiogenic switch in multiple myeloma 127
Autotransplantation in acute leukemia. 127
Gamma-rays from Mössbauer sources: a low-dose approach to cancer therapy 125
Arsenic trioxide in hematological malignancies: The new discovery of an ancient drug 124
DKK-1 and sFRP-3 expression by myeloma cell and bone marrow plasma levels in multiple myeloma and MGUS patients: Potential relationship with bone status. 124
Mossbauer analysis of bone marrow before and after purging with Asta-z 7557 123
RANKL is critically involved in the physiopathology of multiple myeloma 123
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple Myeloma bone disease 122
BCL2 oncogene protein expression in human hematopoietic precursors during fetal life. 121
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 120
Osteopontin is produced by human multiple myeloma cells 120
Pan-aurora kinase inhibitor MK-0457 synergistically potentiates Apo2l/TRAIL cytotoxicity in Multiple Mieloma cells sensitive and resistant to bortezomib 119
Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated marrow. 119
Beta-catenin depended and independent effects induced by myeloma cells in human and murine osteoblasts and osteoblast progenitors. 118
p29ING4 regulates the production of pro-angiogenic molecules by human myeloma cells in normoxic and hypoxic conditions being involved in myeloma-induced angiogenesis. 117
Impact of XIAP protein levels on the survival of myeloma cells 116
Down-modulation of ERK protein kinase activity suppresses human myeloma cell proliferation and myeloma-induced angiogenesis by VEGF inhibition 116
Effects of Mössbauer radiation on bone marrow cultures 116
VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group 115
DNA damage by tobacco smoke and some antiblastic drugs evaluated using the Comet assay 112
Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens 111
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting 111
HUMAN MYELOMA CELLS EXPRESS THE BONE REGULATING GENE RUNX2/CBFA1 AND PRODUCE OSTEOPONTIN THAT IT IS INVOLVED IN MYELOMA INDUCED ANGIOGENESIS 109
Multiple myeloma patient with unusual extramedullary involvement 109
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 108
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 108
The proteasome inhibitor bortezomib affects osteoblastogenesis and bone formation in vitro and in vivo in multiple myeloma patients. 108
Human myeloma cells produce angiopoietin-1: potential relationship with myeloma-induced angiogenesis 105
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 105
IL-7 is produced by myeloma cells in presence of IL-6 104
Purging the bone marrow in non-Hodgkin's lymphomas. Is there any evidence of its value? 103
Role of tumor necrosis factor-related activation-induced cytokine (TRANCE) in multiple myeloma 102
Human myeloma cells express IL-7 mRNA and secrete IL-7 in presence of IL-6 101
The proteasome inhibitor bortezomib stimulates the osteogenic differentiation of mesenchymal cells in vitro and may increase osteoblast formation in vivo in multiple myeloma patients. 101
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide 101
MYELOMA CELLS BLOCK RUNX2/CBFA1 ACTIVITY IN HUMAN BONE MARROW OSTEOBLAST PROGENITORS AND INHIBIT OSTEOBLAST FORMATION AND DIFFERENTIATION 100
Expression of pro-angiogenetic factors by myeloma cells: role of the angiopoietin system 99
Evaluation of amifostine (WR-271) cytoprotection against in vitro bleomycin-induced clastogenicity in human leukocytes by SCGE assay 99
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells 99
Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients 99
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients 99
Totale 13.964
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.358
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.358
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022773 0 2 5 56 16 31 94 137 35 85 80 232
2022/20232.743 357 295 171 193 250 284 53 151 891 11 74 13
2023/2024866 40 105 21 16 75 196 82 89 22 41 69 110
2024/20252.899 52 178 198 202 313 284 47 93 419 283 242 588
2025/20266.673 576 589 763 665 1.006 402 688 208 904 472 240 160
2026/2027427 174 253 0 0 0 0 0 0 0 0 0 0
Totale 19.149